ID Name Structure References (top 5) Molecular Target(s)
1ID:1034
CHOLINE


NSC#:293906
NSC#:402838
Aldrich#:C1379
Aldrich#:C4917
Aldrich#:C9154

Freqency:
in 15 ingredients:

  • 5
  • 114
  • 179
  • 185
  • 233
  • 262
  • 280
  • 392
  • 433
  • 462
  • 614
  • 707
  • 730
  • 890
  • 901
  • in 100 recipes:

  • 3
  • 8
  • 18
  • 20
  • 21
  • 22
  • 26
  • 27
  • 30
  • 36
  • 45
  • 47
  • 48
  • 49
  • 52
  • 56
  • 57
  • 58
  • 63
  • 73
  • 79
  • 80
  • 85
  • 87
  • 91
  • 95
  • 102
  • 105
  • 107
  • 109
  • 110
  • 114
  • 115
  • 119
  • 122
  • 123
  • 128
  • 131
  • 133
  • 135
  • 151
  • 153
  • 155
  • 156
  • 157
  • 160
  • 161
  • 169
  • 170
  • 171
  • 177
  • 180
  • 182
  • 187
  • 190
  • 196
  • 200
  • 203
  • 212
  • 225
  • 226
  • 227
  • 231
  • 233
  • 236
  • 237
  • 241
  • 244
  • 245
  • 247
  • 248
  • 252
  • 255
  • 267
  • 271
  • 272
  • 276
  • 279
  • 280
  • 284
  • 287
  • 289
  • 291
  • 292
  • 294
  • 296
  • 297
  • 300
  • 301
  • 304
  • 305
  • 308
  • 309
  • 311
  • 312
  • 323
  • 324
  • 327
  • 338
  • 340

  • Properties
    C5H14NO    104.17





    1:  Jacobs S.
    An oral drug for leishmaniasis.
    N Engl J Med.    impact factor:   28.857
    2002;  347(22): 1737-8

    2:  Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J.
    Oral miltefosine for Indian visceral leishmaniasis.
    N Engl J Med.    impact factor:   28.857
    2002;  347(22): 1739-46

    3:  Murray HW.
    Kala-azar--progress against a neglected disease.
    N Engl J Med.    impact factor:   28.857
    2002;  347(22): 1793-4

    4:  Babapulle MN, Eisenberg MJ.
    Coated stents for the prevention of restenosis: Part II.
    Circulation.    impact factor:   9.903
    2002;  106(22): 2859-66

    5:  Buttini M, Yu GQ, Shockley K, Huang Y, Jones B, Masliah E, Mallory M, Yeo T, Longo FM, Mucke L.
    Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid beta peptides but not on plaque formation.
    J Neurosci.    impact factor:   8.955
    2002;  22(24): 10539-48

     
    Time used: 515 milliseconds.

    Webpage designed by Dr. Xueliang Fang, last updated on 3/10/2005